Crypto ETFs used to mean one thing: Bitcoin. Then came Ethereum. Now a wave of “altcoin” ETFs is lining up at the SEC’s door — and one of the most interesting is for Injective (INJ). What makes the Injective ETF stand out is not just the token behind it, but a twist in how the fund is built. Here is who filed for it, why it is different, where it stands, and why it could matter for the future of tokenization.
Who Applied for the Injective ETF?
Two issuers are leading the charge. Canary Capital, a crypto-focused asset manager known for filing several altcoin ETFs, submitted paperwork for the first U.S. staked INJ ETF; it filed an updated S-1/A amendment with the SEC on June 25, 2026, and the fund would list on the Cboe exchange. Separately, 21Shares — one of the world’s largest crypto ETP providers — filed for a spot INJ ETF that would hold physical INJ tokens in cold storage, mirroring the structure of approved Bitcoin and Ethereum funds. Between them, they represent serious institutional interest in Injective.
Why This ETF Is Different From Other Crypto ETFs
Most crypto ETFs are simple: they hold the coin, and that is it. The Canary product is a staked ETF — and that changes everything. The INJ held by the fund is staked on the Injective network, and the staking rewards it earns are automatically reinvested back into the fund. In other words, the ETF does not just track INJ’s price; it also compounds a yield on top of it. Compared with a plain spot ETF that only rises and falls with price, a staked ETF gives investors exposure to price and network rewards in a single, regulated product. That is a meaningful upgrade — and a preview of where crypto ETFs are heading.
What Is the Current Status?
As of mid-2026, both filings are pending SEC review — no final approval has been announced. One tailwind: in March 2026, the SEC and CFTC jointly issued an interpretive release setting out a five-category taxonomy for digital assets, which added regulatory clarity around where a token like INJ fits. That kind of clarity makes approval easier to justify, though the release is interpretive guidance rather than binding law.
What Are the Chances of Approval?
The odds look better than they would have a year ago. A more crypto-friendly SEC, a growing list of approved and pending altcoin ETFs, and fresh regulatory guidance all work in Injective’s favour. The main uncertainty is the staking element: regulators are still working out how to treat staking rewards inside a fund, which can add extra review time. So the realistic read is “improving odds, but not a done deal” — approval is plausible, timing is the wild card.
What Could Happen to the INJ Price After Approval?
History offers a clue, not a promise. When spot Bitcoin and Ethereum ETFs were approved, they opened the door to institutional money and were followed by strong inflows. An approved INJ ETF — especially one that also pays a staking yield — could attract buyers who cannot or will not hold crypto directly. That extra demand is often a positive catalyst. But crypto is volatile, “buy the rumour, sell the news” is real, and nothing is guaranteed. Treat an ETF approval as a potential tailwind, not a sure thing.
How Strong Is the Injective Project Itself?
An ETF is only as compelling as the asset behind it, and Injective has real substance. It is a Layer-1 blockchain built specifically for finance, using the Cosmos SDK with custom modules for trading and financial apps. It is fast — block times of roughly 0.67 seconds with instant finality thanks to Tendermint consensus — and in January 2024 it became the first blockchain to natively support a Real-World Asset (RWA) module at the network level. That makes Injective one of the best-positioned chains for tokenizing bonds, treasuries, gold, and other real assets. This is not a meme coin; it is infrastructure.
Conclusion: A Potential Game-Changer for Tokenization
Put the pieces together and the picture is exciting. A staked INJ ETF would connect traditional Wall Street capital to a blockchain that is purpose-built for finance and tokenization. Combine that with the regulatory momentum of the CLARITY Act and the SEC’s new digital-asset taxonomy, and you have a pathway for institutional money to flow into the very rails that tokenization will run on. If it is approved, the Injective ETF could be more than another crypto product — it could be an on-ramp for bringing real-world assets on-chain. That is why so many people are watching this one closely.
This article is for educational purposes only and is not investment advice. Crypto assets are volatile and you can lose money.
Related reading: What Is Tokenization?, Bitcoin vs Ethereum, and The CLARITY Act 2026. Source: Injective.
Izhaq Shah is the founder of GetIntoMarkets. He holds a Master’s in Finance and Commerce, with over 10 years in the financial industry and 15 years of writing experience. He makes investing in stocks, ETFs and crypto simple and practical for everyday people building wealth with confidence.